Current theories about why schizophrenia develops suggest it may be linked to changes in brain development during this ...

Research from the University of Zurich and the University Hospital of Psychiatry, Zurich, suggests that because genetic risk ...

Psychosis involves complex brain interactions, from neurotransmitter imbalances to genetic risks. Understanding its biology ...

Our lives are filled with binary decisions – choices between one of two alternatives. But what's really happening inside our ...

Thousands are fraudulently running pharmacies across India — a racket that came under scanner on April 2 when Delhi’s Anti-Corruption Branch arrested 48 people. Madan Mandal, 45, was on the ...

A Bristol Myers Squibb drug whose landmark FDA approval introduced the first novel mechanism for treating schizophrenia in decades has failed a pivotal test intended to support expanding its use ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

Preliminary analyses suggest that Cobenfy as an adjunctive treatment to an atypical antipsychotic was associated with improvements in symptoms of schizophrenia compared to placebo plus an atypical ...

For patients with disorders such as autism and schizophrenia, mutations in the same gene could require different treatments, according to new research from Yale School of Medicine (YSM). Many ...

Fasting may provide several health benefits, including weight loss, blood sugar management, and protection against medical conditions like cancer and neurodegenerative disorders. Despite its ...

Bristol Myers Squibb has shared results from its Phase III ARISE trial evaluating Cobenfy (xanomeline and trospium chloride) as an add on therapy to atypical antipsychotics in adults with inadequately ...